Drug Type Small molecule drug |
Synonyms vildagliptin, Vildagliptin (JAN/USAN/INN), DSP-7238 + [11] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (25 Sep 2007), |
Regulation- |
Molecular FormulaC17H25N3O2 |
InChIKeySYOKIDBDQMKNDQ-XWTIBIIYSA-N |
CAS Registry274901-16-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07080 | Vildagliptin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | EU | 25 Sep 2007 | |
Diabetes Mellitus, Type 2 | IS | 25 Sep 2007 | |
Diabetes Mellitus, Type 2 | LI | 25 Sep 2007 | |
Diabetes Mellitus, Type 2 | NO | 25 Sep 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 3 | BR | 01 Mar 2014 | |
Diabetic Angiopathies | Phase 3 | GB | 01 May 2010 | |
Insulin Resistance | Phase 3 | GB | 01 May 2010 | |
Microvascular Disease | Phase 3 | GB | 01 May 2010 | |
Hypoglycemia | Phase 3 | CH | 01 Sep 2006 | |
Hyperglycemia | Phase 3 | DE | 20 Feb 2006 | |
Glucose Intolerance | Phase 3 | US | 01 Oct 2005 | |
Prediabetic State | Phase 3 | US | 01 Apr 2005 | |
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | US | 01 Nov 2004 | |
Diabetes Mellitus | Phase 2 | RU | 01 Dec 2008 |
NCT05359432 (Pubmed) Manual | Phase 4 | 120 | lmzztngjnh(gbgjhakiza) = mngefjzugw muiedxbbxu (rdbmbyzble, 0.68) | Positive | 17 Aug 2022 | ||
lmzztngjnh(gbgjhakiza) = nnhddgyukw muiedxbbxu (rdbmbyzble, 1.57) | |||||||
Phase 4 | 346 | wxrfapzgcf(mvqrvdcttr) = eriyxzljij urlicbqvei (kzxibhtzxx ) | - | 01 Jan 2022 | |||
Phase 4 | 80 | mokmzmsbla(ymxdzdznfz) = bavajprkin vocpopgurv (ehtcrkmqmh ) | - | 01 Dec 2020 | |||
mokmzmsbla(ymxdzdznfz) = pupqfqxysw vocpopgurv (ehtcrkmqmh ) | |||||||
Phase 4 | 2,001 | Vildagliptin plus Metformin | ctrlrlpxcf(iuperuhytl): adjusted mean change = 19.23 (95% CI, 8.42 - 30.03) | Positive | 24 Sep 2020 | ||
Metformin | |||||||
Phase 4 | 15 | zvwdoqfeco(yfqtoanbcz) = tkpmhozyxs akfcnxmuou (pfckzucowf ) | Positive | 19 Sep 2019 | |||
Placebo | zvwdoqfeco(yfqtoanbcz) = lowarnngxt akfcnxmuou (pfckzucowf ) | ||||||
Not Applicable | 300 | xfkfhncmrw(arxwnmvtgj) = cgojyezsnk vstkvyhqgu (xxdvxfuhqy, -0.20 to -0.90) | - | 01 Apr 2019 | |||
xfkfhncmrw(arxwnmvtgj) = rbtiesiudz vstkvyhqgu (xxdvxfuhqy, -0.40 to -1.40) | |||||||
Not Applicable | 65 | zkkjlqspcp(ymggoezjem) = vcqjpfcbff kbzhaacvbu (unephaxtmv ) View more | Positive | 04 Oct 2018 | |||
Insulin regimen | zkkjlqspcp(ymggoezjem) = xvmuzusobk kbzhaacvbu (unephaxtmv ) View more | ||||||
Not Applicable | - | 65 | Insulin therapy | akxthuzfnx(jfxcuzqyst) = 8 symptomatic hypoglycemia occurred in G1 and 13 in G2 kcjxonsivr (zpbkhsgrem ) | Positive | 18 May 2018 | |
Vildagliptin + Insulin therapy | |||||||
Phase 4 | 254 | igzkaktlhb(yglidwpxoz) = lnxxzmdcft stwvpubzij (tudhcwmsej ) View more | - | 01 Jan 2018 | |||
Placebo | igzkaktlhb(yglidwpxoz) = mhzoyvlgxx stwvpubzij (tudhcwmsej ) |